Residual Cancer clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
open to eligible people ages 18 years and up
The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: - Sacituzumab govitecan - Atezolizumab
San Francisco, California and other locations
Our lead scientists for Residual Cancer research studies include Hope Rugo.